Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001104659-26-082361
Filing Date
2026-07-10
Accepted
2026-07-10 06:02:59
Documents
2

Document Format Files

Seq Description Document Type Size
1 DEFA14A tm2620160d1_defa14a.htm DEFA14A 17944
2 GRAPHIC tm2620160d1_defa14aimg001.jpg GRAPHIC 33242
  Complete submission text file 0001104659-26-082361.txt   65043
Mailing Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830
Business Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

EIN.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: DEFA14A | Act: 34 | File No.: 001-37759 | Film No.: 261166887
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)